StreetAlpha.app
Home › Stocks › LUCD

Lucid Diagnostics Inc. (LUCD)

$0.37
▼ −3.52%
LAST CLOSE · NOV 20

Lucid Diagnostics makes EsoGuard, a DNA test that screens for precancerous changes in the esophagus in people with chronic heartburn. It last closed at $0.37 on Nov 20, down 3.52% on the day. The next earnings report for LUCD is expected around Thu, Mar 25, 2027. For the quarter ended Sep 2026, LUCD reported EPS of -$0.03 on revenue of $1.2M, with revenue down 0.7% from a year ago. Over its last 8 reports the stock moved an average of 4.2% the session after earnings. Over the last 12 months LUCD insiders bought $245K of stock on the open market and sold $0, according to SEC Form 4 filings.

AI Auto Pilots
Is LUCD in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold LUCD.

Key Stats

Last 12 months
Results
Revenue
$5.4M
+23.6% vs a year ago
Net income
−$48.5M
−892.9% margin
EPS (diluted)
−$0.36
Free cash flow
−$51.8M
−953.5% margin
Valuation
Market cap
$77.1M
207.0M shares
P/E
–
No P/E while losing money
Price to sales
14.2
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Shareholder equity
$5.9M
Shares outstanding
207.0M
At Nov 10
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $500K$500KFY2021FY2022: $377K$377KFY2022FY2023: $2.4M$2.4MFY2023FY2024: $4.3M$4.3MFY2024FY2025: $4.7M$4.7MFY2025

From LUCD's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Next report
Mar 25
Estimated date · Time not announced
Reported EPS
-$0.03
Quarter ended Sep 2026
Year ago EPS
-$0.10
Same quarter last year
Revenue
$1.2M
−0.7% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.18Dec '24Mar 2025: -$0.52Mar '25Jun 2025: -$0.08Jun '25Sep 2025: -$0.10Sep '25Dec 2025: -$0.10Dec '25Mar 2026: -$0.17Mar '26Jun 2026: -$0.08Jun '26Sep 2026: -$0.03Sep '26Latest -$0.03
Revenue by quarter
Dec 2024: $1.2MDec '24Mar 2025: $828,000Mar '25Jun 2025: $1.2MJun '25Sep 2025: $1.2MSep '25Dec 2025: $1.5MDec '25Mar 2026: $1.3MMar '26Jun 2026: $1.5MJun '26Sep 2026: $1.2MSep '26Latest $1.2M
How LUCD moved after its last 8 reports
Average move the session after a report ±4.2%
Nov 12, 2026Time not announced+9.2%
Aug 13, 2026Time not announced−2.0%
May 14, 2026Time not announced0.0%
Mar 26, 2026Time not announced−3.4%
Nov 12, 2025Time not announced+6.7%
Aug 13, 2025Time not announced−1.6%
May 14, 2025Time not announced+7.6%
Mar 25, 2025Time not announced+3.3%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on LUCDStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on LUCD
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on LUCD

Technical Analysis

LUCD · as of the Nov 20 close · updated each morning
Downtrend

The stock is 11% below its 20 day and 49% below its 50 day average. It is 159% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 39). The nearest support is the Pivot at $0.37, and the nearest resistance the Pivot R1 at $0.39.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityHigh, 14.6%/day
Key levels
$1.6352 week high+340.5%
$0.96200 day average+159.5%
$0.76100 day average+105.4%
$0.5650 day average+51.4%
$0.48Swing high (Nov 4)+29.7%
$0.4120 day average+10.8%
$0.39Pivot R1+5.4%
$0.37Pivot+0.0%
$0.37Last close
$0.35Pivot S1−5.4%
$0.3052 week low−18.9%
$0.30Swing low (Oct 22)−18.9%
Indicators
RSI (14)39.01Weak, oversold below 30Neutral
MACD-0.04Above its signal lineBullish
Stochastic19.2Near the bottom of its rangeOversold
ADX (14)13.2No clear trend
Williams %R-86.8Oversold below −80, overbought above −20Oversold
CCI (20)-136.9Oversold below −100, overbought above 100Oversold
Rate of change−6.4%Change over 10 sessionsBearish
ATR (14)$0.05Typical daily range, 14.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for LUCD

What happened before

See how LUCD did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow LUCD usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How LUCD has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for LUCDHow many large options trades hit LUCD, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

LUCD Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●47 buying vs 47 selling
  • ▼Held by funds -0.5 pts
  • ●Funds holding +0
  • ●Superinvestors: 1 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding1161160.0%
In funds' top 1000–
Held by funds29.1%29.7%−0.5 pts
New / increased15 / 3225 / 59−44.0%
Reduced / sold out30 / 1712 / 10+113.6%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See LUCD institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

LUCD Insider Trading

All filings →
Insider trading · 12 months
Insiders are buying
Bought$245K1 buy · 1 insider
Sold$00 sales · 0 insiders
2026-05 bought $245KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
May 20Dennis MatheisDirectorBuy245,000$1.00$245K
Aug 20, 2025Dennis MatheisDirectorBuy100,000$1.02$102K
May 22, 2025Dennis MatheisDirectorBuy350,000$1.31$458K
Every insider buy and sale for LUCD over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See LUCD insider trades →

From SEC Form 4 filings by LUCD's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether LUCD is in one of them and how their past LUCD trades turned out.

LUCD in the AI portfolios
Loading…

LUCD News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered LUCD in an article yet. Here's the latest on the wider market.

LUCD in the news

About Lucid Diagnostics

Lucid Diagnostics is a medical diagnostics company based in New York. Its main product is EsoGuard, a DNA test that looks for precancerous changes in the esophagus, run on cell samples collected with the EsoCheck swallowable capsule device. The company targets people with chronic heartburn, also known as GERD, who are at risk of esophageal cancer, and it offers testing through its own test centers, mobile units, physician office programs and health system arrangements.

Headquarters
New York, NY